Stocksigma LogoStocksigma Logo

Astec LifeSciences Reports Widened Q2 FY27 Consolidated Net Loss Amid Sluggish Revenue

Astec LifeSciences reported consolidated revenue from operations of ₹7,202.01 lakh for the quarter ended 30th Sep'26, down 2.31% YoY from ₹7,372.06 lakh

Astec LifeSciences Reports Widened Q2 FY27 Consolidated Net Loss Amid Sluggish Revenue

Astec Lifesciences Ltd · Outcome · 26 Oct 2026, 10:26 pm

Astec LifeSciences Reports Widened Q2 FY27 Consolidated Net Loss Amid Sluggish Revenue Astec LifeSciences reported consolidated revenue from operations of ₹7,202.01 lakh for the quarter ended 30th Sep'26, down 2.31% YoY from ₹7,372.06 lakh and 13.81% QoQ from ₹8,356.43 lakh. Consolidated net loss widened significantly to ₹3,739.71 lakh compared to a loss of ₹2,441.70 lakh in Q2 FY26 and ₹1,870.73 lakh in Q1 FY27. Operating margin deteriorated sharply to -27.48% versus -9.07% YoY. Diluted EPS stood at ₹(16.79). Total debt-to-assets remained at 0.42, while net cash generated from operating activities reached ₹12,195.71 lakh for H1 FY27.

Original exchange filing (PDF)

More announcements from Astec Lifesciences Ltd

All Astec Lifesciences Ltd announcements